The FDA approved AbbVie’s tavapadon, to be marketed as Juvmo, for adults with Parkinson’s disease on September 25, 2026, according to Reuters.
Juvmo is a once-daily oral medicine that mimics dopamine by activating D1 and D5 dopamine receptors—a different approach from levodopa and older, less selective dopamine agonists.
Approval was based on AbbVie’s late-stage TEMPO trial program, which found improved Parkinson’s symptoms. In trials, reported common side effects included nausea, dizziness, and headache.
The approval adds an oral treatment option; it does not replace existing therapies, and individual suitability and side effects should be discussed with a clinician.
Sources:
US FDA approves AbbVie's drug for Parkinson's disease
New Continuous Pump Medication for ...
Parkinson's Disease Treatment Pipeline
FDA approves AbbVie's once-daily Parkinson's pill, Juvmo
AbbVie gets continuous Parkinson's drug over the line in US
US FDA Approves AbbVie's Drug for Parkinson's Disease
AbbVie Submits NDA for Tavapadon: A Breakthrough in Parkinson's
FDA approves VYALEV for advanced Parkinson's treatment
AbbVie's Juvmo (Tavapadon) Approved for Parkinson's, First D1/D5...
被低估30年，这个方向终于迎来FDA批准！| Bilingual_腾讯新闻
Vyalev gets FDA approval for advanced Parkinson's disease